• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: PERCEPTIVE ADVISORS LLC bought $55,070,983 worth of Common Stock (5,507,063 units at $10.00), increasing direct ownership by 1% to 497,038 units

    6/11/21 5:45:24 PM ET
    $ARYA
    Business Services
    Finance
    Get the next $ARYA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    PERCEPTIVE ADVISORS LLC

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Nautilus Biotechnology, Inc. [ NAUT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Former Director
    3. Date of Earliest Transaction (Month/Day/Year)
    05/24/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/24/2021 P 7,063 A $10.05 497,038 D
    Common Stock 06/09/2021 P 5,500,000 A $10 5,997,038 I See Footnote(1)
    Common Stock 06/09/2021 J 2,914,113 A (2) 8,911,151 I See Footnote(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    PERCEPTIVE ADVISORS LLC

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    EDELMAN JOSEPH

    (Last) (First) (Middle)
    51 ASTOR PLACE, 10TH FLOOR

    (Street)
    NEW YORK NY 10003

    (City) (State) (Zip)
    Explanation of Responses:
    1. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
    2. Acquired pursuant to the business combination by and among ARYA Sciences Acquisition Corp III, Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. ("Old Nautilus") in exchange for shares of Old Nautilus previously held by the Master Fund.
    /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member 06/11/2021
    /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member 06/11/2021
    /s/ Joseph Edelman 06/11/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MarketBeat Ranks Stocks with Most Insider Buying in June 2021

      SIOUX FALLS, S.D., July 8, 2021 /PRNewswire-PRWeb/ -- MarketBeat, a leading source for stock market data and research tools, has published a monthly list ranking The 10 Stocks with the Most Insider Buying in June 2021. An insider trade occurs when a company executive or individual who has non-public information about a company buys or sells shares of that company's stock. The level of stock that insiders are buying is a potential indicator of the stock's future performance. The MarketBeat editorial team compiled the 10 stocks with the most insider trading by utilizing the company's Stocks with the Most Insider Buying Report. For stocks with the most insider buying, software companies and s

      7/8/21 7:00:00 PM ET
      $UHAL
      $FAII
      $HEC
      $ARYA
      Rental/Leasing Companies
      Consumer Discretionary
      Business Services
      Finance
    • Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

      Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021Publicly traded company renamed Nautilus Biotechnology, Inc.Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account and a concurrent PIPE financing of $200 million SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis pla

      6/9/21 10:05:00 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

      NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III ("ARYA") (NASDAQ:ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the "General Meeting") remotely by teleconference rather than in person. The purpose of the General Meeting is to vote on certain proposals relating to the previously announced Business Combination Agreement, dated as of February 7, 2021 (the "Business

      6/1/21 5:01:46 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: PERCEPTIVE ADVISORS LLC bought $55,070,983 worth of Common Stock (5,507,063 units at $10.00), increasing direct ownership by 1% to 497,038 units

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:45:24 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 4: ALTMAN MICHAEL SETH converted 4,146,500 units into Common Stock

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:32:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 3 filed by Epperly Melissa B,

      3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/9/21 9:41:46 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/30/21 2:26:38 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/21/21 5:00:58 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/16/21 5:10:03 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    SEC Filings

    See more
    • SEC Form D filed by ARYA Sciences Acquisition Corp III

      D - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/22/21 4:58:45 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Discl

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/9/21 8:55:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 425 filed by ARYA Sciences Acquisition Corp III

      425 - ARYA Sciences Acquisition Corp III (0001808805) (Subject)

      6/8/21 5:13:44 PM ET
      $ARYA
      Business Services
      Finance